Press release
Polymyositis Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies by DelveInsight
Polymyositis Treatment Market
To Know in detail about the Polymyositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Polymyositis Market Forecast
https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key facts of the Polymyositis Market Report:
• The Polymyositis market size was valued approximately ~USD 114 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In December 2024, RESTEM, a clinical-stage biotechnology company specializing in off-the-shelf, next-generation cell therapies aimed at immune system modulation, announced that the U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to its umbilical cord outer lining stem cells (ULSCs) program for treating Polymyositis (PM) and Dermatomyositis (DM).
• In 2023, Germany had the largest Polymyositis market size among EU countries, valued at approximately USD 6 million, while Spain recorded the smallest market size at around USD 2 million.
• The anticipated introduction of new therapies, including Anifrolumab (SAPHNELO), PF-06823859, and Enpatoran (M5049), among others, is expected to drive changes in the total market size of Polymyositis in the coming years.
• In 2023, the United States had the largest market size for Polymyositis among the 7MM, reaching approximately USD 86 million. This figure is anticipated to grow at a compound annual growth rate (CAGR) of 15.8% throughout the forecast period.
• According to DelveInsight's analysis, the estimated total number of diagnosed prevalent cases of Polymyositis in the 7MM was approximately 80,000 in 2023.
• In 2023, Germany had the highest number of diagnosed prevalent cases of Polymyositis among European countries, with around 9,000 cases, followed by France with approximately 7,000 cases. In contrast, Spain had the lowest prevalent population, with about 3,000 cases.
• In 2023, Japan reported around 12,000 diagnosed prevalent cases of Polymyositis, representing roughly 16% of the total cases across the 7MM.
• According to DelveInsight's analysis, females in Japan were more commonly affected by Polymyositis than males, with around 9,000 female cases compared to 3,000 male cases in 2023.
• Key Polymyositis Companies: Argenx, Immunoforge Co. Ltd., Chester Oddis, Kezar Life Sciences, Inc., Mallinckrodt, Merck KGaA, Astellas Pharma Inc, Genentech, Immunoforge Co. Ltd., Pfizer, Bristol-Myers Squibb, and others
• Key Polymyositis Therapies: Efgartigimod, PF1801, tocilizumab, KZR-616, Adrenocorticotropic Hormone Gel, M5049 high dose, Tacrolimus, Rituximab, Froniglutide, PF-06823859, Abatacept subcutaneous, and others
• The Polymyositis epidemiology based on gender analyzed that Polymyositis affects females more as compared to males
• The Polymyositis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Polymyositis pipeline products will significantly revolutionize the Polymyositis market dynamics.
Polymyositis Overview
Polymyositis is a rare, chronic inflammatory muscle disease characterized by muscle weakness and inflammation. It belongs to a group of diseases called inflammatory myopathies and primarily affects the skeletal muscles, which are responsible for movement.
Get a Free sample for the Polymyositis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Polymyositis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Polymyositis Epidemiology Segmentation:
The Polymyositis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Polymyositis
• Prevalent Cases of Polymyositis by severity
• Gender-specific Prevalence of Polymyositis
• Diagnosed Cases of Episodic and Chronic Polymyositis
Download the report to understand which factors are driving Polymyositis epidemiology trends @ Polymyositis Epidemiology Forecast
https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Polymyositis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Polymyositis market or expected to get launched during the study period. The analysis covers Polymyositis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Polymyositis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Polymyositis Therapies and Key Companies
• Efgartigimod: Argenx
• PF1801: Immunoforge Co. Ltd.
• tocilizumab: Chester Oddis
• KZR-616: Kezar Life Sciences, Inc.
• Adrenocorticotropic Hormone Gel: Mallinckrodt
• M5049 high dose: Merck KGaA
• Tacrolimus: Astellas Pharma Inc
• Rituximab: Genentech
• Froniglutide: Immunoforge Co. Ltd.
• PF-06823859: Pfizer
• Abatacept subcutaneous: Bristol-Myers Squibb
Discover more about therapies set to grab major Polymyositis market share @ Polymyositis Treatment Landscape
https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Polymyositis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Polymyositis Companies: Argenx, Immunoforge Co. Ltd., Chester Oddis, Kezar Life Sciences, Inc., Mallinckrodt, Merck KGaA, Astellas Pharma Inc, Genentech, Immunoforge Co. Ltd., Pfizer, Bristol-Myers Squibb, and others
• Key Polymyositis Therapies: Efgartigimod, PF1801, tocilizumab, KZR-616, Adrenocorticotropic Hormone Gel, M5049 high dose, Tacrolimus, Rituximab, Froniglutide, PF-06823859, Abatacept subcutaneous, and others
• Polymyositis Therapeutic Assessment: Polymyositis current marketed and Polymyositis emerging therapies
• Polymyositis Market Dynamics: Polymyositis market drivers and Polymyositis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Polymyositis Unmet Needs, KOL's views, Analyst's views, Polymyositis Market Access and Reimbursement
To know more about Polymyositis companies working in the treatment market, visit @ Polymyositis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Polymyositis Market Report Introduction
2. Executive Summary for Polymyositis
3. SWOT analysis of Polymyositis
4. Polymyositis Patient Share (%) Overview at a Glance
5. Polymyositis Market Overview at a Glance
6. Polymyositis Disease Background and Overview
7. Polymyositis Epidemiology and Patient Population
8. Country-Specific Patient Population of Polymyositis
9. Polymyositis Current Treatment and Medical Practices
10. Polymyositis Unmet Needs
11. Polymyositis Emerging Therapies
12. Polymyositis Market Outlook
13. Country-Wise Polymyositis Market Analysis (2020-2034)
14. Polymyositis Market Access and Reimbursement of Therapies
15. Polymyositis Market Drivers
16. Polymyositis Market Barriers
17. Polymyositis Appendix
18. Polymyositis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Polymyositis Pipeline https://www.delveinsight.com/report-store/polymyositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
"Polymyositis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Polymyositis market. A detailed picture of the Polymyositis pipeline landscape is provided, which includes the disease overview and Polymyositis treatment guidelines.
Trending Reports:
• Bacterial Skin Diseases Market: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Bcl-2 Inhibitors Market: https://www.delveinsight.com/report-store/bcl2-inhibitors-market-forecast
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Cardiac Insufficiency Market: https://www.delveinsight.com/report-store/congestive-heart-failure-market
• Central Retinal Venous Occulsion Market: https://www.delveinsight.com/report-store/retinal-vein-occlusion-market
• Cervical Intraepithelial Neoplasia Market: https://www.delveinsight.com/report-store/cervical-cancer-market
• Chronic Hepatitis Delta Virus Market: https://www.delveinsight.com/report-store/hepatitis-d-market
• Chronic Insomnia Market: https://www.delveinsight.com/report-store/insomnia-market
• Concussions Market Size: https://www.delveinsight.com/report-store/concussions-market
• Dermal Mycosis Market: https://www.delveinsight.com/report-store/dermal-mycosis-pipeline-insight
• Epithelial Ovarian Cancer Market: https://www.delveinsight.com/report-store/ovarian-cancer-market
• Gastroenteropancreatic Neuroendocrine Tumors Market: https://www.delveinsight.com/blog/gastroenteropancreatic-neuroendocrine-tumours-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Global Electrophysiology Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Goitre Market: https://www.delveinsight.com/report-store/goitre-market
• Gout Market: https://www.delveinsight.com/report-store/gout-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Hemophilia B Market: https://www.delveinsight.com/report-store/hemophilia-b-market
• Hypoparathyroidism Market: https://www.delveinsight.com/report-store/hypoparathyroidism-market
• Neurofibromatosis 2 Market: https://www.delveinsight.com/report-store/neurofibromatosis-2-market
• Neuromodulation Devices Market: https://www.delveinsight.com/report-store/neuromodulation-devices-market
• Neurotrophic Keratitis Market: https://www.delveinsight.com/report-store/neurotrophic-keratitis-market
• Neurovascular Thrombectomy Devices Market: https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market
• Nipah Virus Infection Market: https://www.delveinsight.com/report-store/nipah-virus-niv-infection-market
• Opioid Induced Constipation Market: https://www.delveinsight.com/report-store/opioid-induced-constipation-market
• Penicillinbinding Proteins Market: https://www.delveinsight.com/report-store/penicillin-binding-proteins-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/
Case Study: https://www.delveinsight.com/case-study/conference-intelligence-product-assessment
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Polymyositis Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies by DelveInsight here
News-ID: 3826202 • Views: …
More Releases from DelveInsight Business Research
Autosomal Dominant Optic Atrophy Market Set for Robust Growth Through 2034, Driv …
The autosomal dominant optic atrophy treatment market is experiencing significant expansion, driven by increasing disease awareness, rising prevalence, and R&D in precision medicine from key pharmaceutical players, including PYC Therapeutics and Stoke Therapeutics, among others.
DelveInsight's "Autosomal Dominant Optic Atrophy - Market Insight, Epidemiology And Market Forecast - 2034" report delivers an in-depth understanding of the ADOA treatment market, historical and forecasted epidemiology, as well as market trends across the US,…
Severe Asthma Market Set for Robust Growth Through 2034, Driven by Breakthrough …
The severe asthma treatment market is experiencing robust expansion, driven by rising disease prevalence, improved diagnostic approaches, and breakthrough therapeutic developments from key pharmaceutical players, including AstraZeneca, GlaxoSmithKline, Amgen, Teva Pharmaceutical Industries, Novartis, Sanofi, Regeneron Pharmaceutical, Boehringer Ingelheim Pharmaceuticals, Kyorin Pharmaceutical, Pfizer, Chiesi Farmaceutici, AB Science, Avalo Therapeutics, and Theravance Biopharma, among others.
DelveInsight's "Severe Asthma Market Insights, Epidemiology, and Market Forecast-2034" report delivers a comprehensive understanding of the severe asthma…
Systemic Lupus Erythematosus Pipeline Heats Up as 120+ Companies Advance Cutting …
The systemic lupus erythematosus (SLE) treatment pipeline is experiencing unprecedented expansion, driven by increasing disease awareness, rising prevalence, and breakthrough therapies from key pharmaceutical players, including Biogen, Idorsia Pharmaceuticals, AbbVie, BioSenic, Roche, Novartis, Allogene Therapeutics, Adicet Bio, and numerous other leading companies advancing innovative treatments through robust clinical development programs.
DelveInsight's "Systemic Lupus Erythematosus Pipeline Insight, 2025" report delivers comprehensive insights about 120+ companies and 140+ pipeline drugs currently in the…
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
More Releases for Polymyositis
Polymyositis Market on Track for Major Expansion by 2034, According to DelveInsi …
DelveInsight's "Polymyositis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Polymyositis, historical and forecasted epidemiology as well as the Polymyositis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Polymyositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Polymyositis Market Forecast
https://www.delveinsight.com/sample-request/polymyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Polymyositis…
Polymyositis Market Outlook 2025-2034: Trends, Growth, and Forecast Analysis
Polymyositis (PM) is a rare, chronic autoimmune disease that causes muscle weakness and inflammation. It affects the muscles responsible for movement, leading to significant disability and a reduction in quality of life. As the understanding of autoimmune diseases expands and new therapeutic options emerge, the polymyositis market is experiencing significant growth. This article explores the key drivers, market trends, challenges, and growth opportunities in the polymyositis market, projected to expand…
Polymyositis Clinical Pipeline | 7+ Innovators Pushing the Boundaries of Treatme …
The Polymyositis market is advancing with groundbreaking research and innovative therapeutic developments.
DelveInsight's 'Polymyositis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Polymyositis therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Polymyositis pipeline domain.
For Polymyositis emerging drugs, the Polymyositis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product…
Polymyositis Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Polymyositis Pipeline Insight 2024" report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Polymyositis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Polymyositis Research. Learn more about our innovative pipeline…
Polymyositis Treatment Market Size Research Report 2024
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Polymyositis Treatment Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in…
Polymyositis Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Polymyositis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Polymyositis, historical and forecasted epidemiology as well as the Polymyositis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Polymyositis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Polymyositis market size from 2019 to 2032, segmented…
